Dong Maoqing, Zang Mengwei, Pinon Delia I, Li Zhijun, Lybrand Terry P, Miller Laurence J
Center for Basic Research in Digestive Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.
Mol Endocrinol. 2002 Nov;16(11):2490-501. doi: 10.1210/me.2002-0111.
The amino terminus of the secretin receptor (SecR) is known to be critical for natural agonist action, although the role it plays is still unclear. We have demonstrated that photolabile residues within both the amino-terminal (position 6) and carboxyl-terminal (positions 22 and 26) halves of secretin each covalently label receptor amino-terminal tail residues [Dong et al., J Biol Chem, 274:19161-19167 (1999), 274:903-909 (1999), and 275:26032-26039 (2000)]. Here, we extend this series of studies with an additional probe having its site of covalent attachment in a distinct region of the peptide, between amino- and carboxyl-terminal helical domains. This probe incorporated a photolabile (epsilon-p-benzoylbenzoyl)lysine in position 18 and a site for oxidative radioiodination [(tyrosine(10),(benzoyl-benzoyl)lysine(18))rat secretin-27]. This analog represented a full agonist, stimulating cAMP accumulation in Chinese hamster ovary-SecR cells in a concentration-dependent manner. It bound to the SecR specifically and saturably, and was able to efficiently label that molecule within its amino terminus. Sequential specific cleavage, purification, and sequencing demonstrated that this probe labeled receptor residue arginine(14), in the same subdomain as that labeled by previous probes. Consistent with the importance of this residue, alanine replacement mutagenesis (R14A) resulted in substantial reductions in the potency (127-fold) and binding affinity (400-fold) of secretin relative to its action at the wild-type receptor. We have been able to accommodate all four extant pairs of residue-residue approximations between divergent regions of the secretin pharmacophore and the first forty residues of the SecR into a credible molecular model of this interaction. Additional experimentally derived constraints will be necessary to determine the spatial positioning of this complex with the remainder of the SecR.
已知促胰液素受体(SecR)的氨基末端对于天然激动剂的作用至关重要,尽管其发挥的作用仍不清楚。我们已经证明,促胰液素氨基末端(第6位)和羧基末端(第22和26位)两半部分内的光不稳定残基各自共价标记受体氨基末端尾部残基[董等人,《生物化学杂志》,274:19161 - 19167(1999),274:903 - 909(1999),以及275:26032 - 26039(2000)]。在此,我们用另一种探针扩展了这一系列研究,该探针的共价连接位点位于肽的一个不同区域,在氨基末端和羧基末端螺旋结构域之间。该探针在第18位掺入了一个光不稳定的(ε - 对苯甲酰苯甲酰)赖氨酸和一个用于氧化放射性碘化的位点[(酪氨酸(10),(苯甲酰 - 苯甲酰)赖氨酸(18))大鼠促胰液素 - 27]。这种类似物是一种完全激动剂,以浓度依赖的方式刺激中国仓鼠卵巢 - SecR细胞中的环磷酸腺苷(cAMP)积累。它特异性且饱和地结合到SecR上,并且能够有效地在其氨基末端内标记该分子。连续的特异性切割、纯化和测序表明,该探针标记了受体残基精氨酸(14),与先前探针标记的位于相同的亚结构域。与该残基的重要性一致,丙氨酸替代诱变(R14A)导致促胰液素相对于其在野生型受体上的作用,效力(127倍)和结合亲和力(400倍)大幅降低。我们已经能够将促胰液素药效基团不同区域与SecR的前四十个残基之间所有四对现存的残基 - 残基近似关系纳入这种相互作用的一个可信分子模型中。需要额外的实验得出的限制条件来确定该复合物与SecR其余部分的空间定位。